# Financial Times

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/financial-times
Canonical HTML page: https://gethealthbrief.com/entity/financial-times

## Recent coverage (2 stories)

### AstraZeneca-BMS £300bn Merger Could Reshape Global Drug Access and Pricing
2026-08-03 09:57:07 · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-healthcare-impact

### AZN-BMS $400B Talks: What It Means for Drug Prices and Access
2026-08-02 23:37:50 · Sentiment: Neutral · Impact: 9/10 · Sources: 2

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.